Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222170 · ClinicalTrials.gov registry record · Phase 2
Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)
A Phase 2 study, sponsored by University of Kansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00222170 is a Phase 2 study that has completed, run by University of Kansas. The registered enrollment target is 24 participants.
The verdict
NCT00222170, a Phase 2 study, has completed, sponsored by University of Kansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the production of mucin in GERD/RE subjects before and after 8 weeks of treatment with rabeprazole.
Interventions
- DRUG Rabeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222170
The ClinicalTrials.gov registry entry for NCT00222170 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rabeprazole is the first listed.
NCT00222170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00222170 about?
NCT00222170 is a clinical study titled "Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)". The purpose of this study is to determine the production of mucin in GERD/RE subjects before and after 8 weeks of treatment with rabeprazole.
What is the current status of trial NCT00222170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2005-05. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00222170?
The interventions under investigation include: Rabeprazole (DRUG).
Who is sponsoring clinical trial NCT00222170?
This trial is sponsored by University of Kansas, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.